This clearance positions the company closer to its goal of commercializing its technology and increasing shareholder value, said Manhattan Scientifics. This patented new form of titanium metal originally
This agreement will provide access to one of ProMetic’s proprietary affinity adsorbents for incorporation into this company’s manufacturing process. Steve Burton, CEO of ProMetic BioSciences, said: “This agreement
The study is designed to assess the effectiveness of a panel of Neogenix monoclonal antibodies as diagnostic markers for colorectal and pancreatic cancer. The diagnostic properties of these
The companies, who initiated the collaboration in December 2006, are moving the program into preclinical development. As a result, Symphogen will receive a milestone payment from Meiji under
The AnalyST implantable cardioverter defibrillator (ICD) with ST Monitoring is said to be the industry’s first device to continuously monitor specific changes in the heart’s electrical system which
The company’s decision to submit a clinical trial application (CTA) follows a board review of progress with Atu027 and, in particular, consideration of recent discussions with BfArM, the
The European approval provides a significantly broader indication for peginterferon alfa-2a and establishes a new standard of care for treatment-experienced patients with the most difficult-to-treat virus, the company
The first study 030 compared the pulmonary safety of meal-time inhalation of Afresa versus usual care in over 2000 patients with type 1 and type 2 diabetes. The
According to the company, approximately 19 end stage blood cancer patients were treated with no cases of grade III/IV acute graft versus host disease (GVHD) occurring within the
The program enrolled 282 patients who underwent cataract surgery in two US multi-center, randomized, double-masked, parallel-group, vehicle-controlled studies to evaluate Xibrom (0.09% bromfenac sodium ophthalmic solution) dosed once
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.